Basic and Clinical Status

  • Seymour Reichlin

Part of the Serono Symposia, USA book series (SERONOSYMP)

Table of contents

  1. Front Matter
    Pages i-xi
  2. Biosynthesis and Processing

    1. Front Matter
      Pages 1-1
    2. Jack E. Dixon, Timothy E. Hayes, Marie Tavianini, Bernard A. Roos, Ourania Andrisani
      Pages 13-19
    3. Richard H. Goodman, Gail Mandel, Kevin A. Sevarino, Marc R. Montminy
      Pages 21-32
    4. Bryan D. Noe, Robert B. Mackin, John K. McDonald, Philip C. Andrews, Jack E. Dixon, Joachim Spiess
      Pages 59-70
  3. Mechanisms of Action

    1. Front Matter
      Pages 81-81
    2. Ruth F. Nutt, C. Dylion Colton, Richard Saperstein, Daniel F. Veber
      Pages 83-88
    3. Coimbatore B. Srikant, Yogesh C. Patel
      Pages 89-102
    4. John A. Williams, Christiane Susini
      Pages 103-109
    5. Agnes Schonbrunn, Bruce D. Koch
      Pages 121-135
  4. Role of Somatostatin in Nervous System Function and Controversies in Somatostatin Research

    1. Front Matter
      Pages 147-147
    2. Charles B. Nemeroff, Thomas J. Walsh, Garth Bissette
      Pages 157-167
    3. David R. Rubinow, Robert M. Post, Candace Davis, Allen Doran
      Pages 183-192
    4. K. H. Usadel, H. Kessler, G. Rohr, K. Kusterer, K. D. Palitzsch, U. Schwedes
      Pages 193-200
    5. Werner Creutzfeldt
      Pages 201-208
    6. Volker Schusdziarra
      Pages 209-217
  5. Somatostatin in Gastrointestinal Function

    1. Front Matter
      Pages 219-219
    2. Tadataka Yamada
      Pages 221-228
    3. Tsutomu Chiba, Jung Park, Tadataka Yamada
      Pages 229-237
    4. Travis E. Solomon
      Pages 275-283
    5. Mats Mogard, Vern Maxwell, Terry Reedy, Gary Van Deventer, Janet Elashoff, John Walsh
      Pages 285-290
  6. Clinical Applications

    1. Front Matter
      Pages 291-291
    2. J. Gerich, I. Gottesman, G. Bolli, P. Campbell, F. Kennedy
      Pages 303-311
    3. J. N. Baxter, S. A. Jenkins, R. Shields
      Pages 319-326
    4. G. M. Besser, J. A. H. Wass
      Pages 333-336
    5. George Tolis, Angelos Yotis, Emilio del Pozo, Alan Harris
      Pages 337-341
    6. Ulrich Leuschner, Karl Uberla, Klaus-Henning Usadel
      Pages 357-364
  7. Back Matter
    Pages 365-373

About this book


The discovery of hypothalamic factors that inhibited growth hormone secretion and of pancreatic factors that inhibited insulin secretion were the first clues to the existence of somatostatin. During the course of efforts to isolate growth hormone releasing factor, Krulich, McCann and Dhariwal found that hypothalamic extracts contained a potent inhibitor of growth hormone secretion. They postulated that growth hormone secretion was under a dual control system, one inhibitory and the other excitatory (I) . In studies being carried out at about the same time, Hellman and Lernmark found a factor in pancreatic extracts that inhibited insulin secretion (2). They postulated that islet cell function was regulated by local hormonal factors. With the isolation and chemical characterization of somatostatin by Brazeau and colleagues (3), and the availability of relatively large amounts of the synthetic peptide for research, it has been possible to demonstrate that both predictions were true. Subsequent work revealed that somatostatin, as initially isolated (somatostatin 14), was but one of several related peptides, part of a multigene family, with tissue specific processing. Many of the details of biosynthesis and genetic control have been worked out, and this molecule has served many workers as a model gut-brain peptide for detailed study. The peptides are widely distributed in tissues and exert an extraordinary range of effects on most glandular secretions, both internal and external.


Insulin Secretion Pancreas biosynthesis brain diabetes growth homeostasis hormone insulin molecule neurotransmitter peptides research tissue treatment

Editors and affiliations

  • Seymour Reichlin
    • 1
  1. 1.Tufts UniversityBostonUSA

Bibliographic information